Inactive Instrument

Inspyr Therapeutics, Inc. Share Price Other OTC

Equities

NSPX

US45782A4031

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2021 - Sales 2022 - Capitalization 241K 20.11M
Net income 2021 2M 167M Net income 2022 -1M -83.46M EV / Sales 2021 -
Net cash position 2021 197K 16.44M Net Debt 2022 305K 25.46M EV / Sales 2022 -
P/E ratio 2021
-0.4 x
P/E ratio 2022
-0.23 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Rebus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Rebus Holdings, Inc. Auditor Raises 'Going Concern' Doubt CI
Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Rebus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Rebus Holdings, Inc. Auditor Raises 'Going Concern' Doubt CI
Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Inspyr Therapeutics Announces New Holding Company Structure CI
Inspyr Therapeutics, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021 CI
Inspyr Therapeutics, Inc. Announces Resignation of Michael Cain as Chief Executive Officer CI
Inspyr Therapeutics, Inc. announced that it has received $0.6 million in funding CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news
Managers TitleAgeSince
Chief Executive Officer 53 -
Chief Tech/Sci/R&D Officer - 11/16/11
Members of the board TitleAgeSince
Director/Board Member 69 01/08/01
Chief Executive Officer 53 -
Director/Board Member 68 12/16/12
More insiders
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW